Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

被引：2
|
作者：
Han, Lina [1 ]
Zhang, Qi [1 ]
Shi, Ce [2 ]
Cavazos, Antonio [1 ]
Ruvolo, Vivian [1 ]
Leverson, Joel [3 ]
Monique, Dail [4 ]
Phillips, Darren C. [3 ]
Chen, Jun [3 ]
Jin, Sha S. [3 ]
Jacamo, Rodrigo Omar [1 ]
Daver, Naval [1 ]
Jabbour, Elias J. [1 ]
Kantarjian, Hagop M. [1 ]
Andreeff, Michael [1 ]
Sampath, Deepak [4 ]
Konopleva, Marina [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Leukemia, Harbin, Peoples R China
[3] AbbVie Inc, N Chicago, IL USA
[4] Genentech Inc, San Francisco, CA USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.97.97
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
97
引用
收藏
页数：5
相关论文
共 45 条
  • [21] Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Salles, Gilles A.
    Boyd, Thomas E.
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Hallek, Michael
    Eichhorst, Barbara F.
    Kozloff, Mark
    Cartron, Guillaume
    Li, Yan
    Hilger, James
    Mobasher, Mehrdad
    Stilgenbauer, Stephan
    BLOOD, 2015, 126 (23)
  • [22] Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
    Flinn, Ian W.
    Brunvand, Mark
    Choi, Michael Y.
    Dyer, Martin J. S.
    Gribben, John
    Hillmen, Peter
    Jones, Jeffrey
    Li, Yan
    Mobasher, Mehrdad
    Vosganian, Gregory
    Kipps, Thomas J.
    BLOOD, 2015, 126 (23)
  • [23] Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Roberts, Andrew W.
    Ma, Shuo
    Brander, Danielle M.
    Kipps, Thomas J.
    Barrientos, Jacqueline C.
    Davids, Matthew S.
    Anderson, Mary Ann
    Tam, Constantine
    Mason-Bright, Tanita
    Rudersdorf, Nikita K.
    Gressick, Lori
    Yang, Jianning
    Munasinghe, Wijith
    Zhu, Ming
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Seymour, John F.
    BLOOD, 2014, 124 (21)
  • [24] THE BCL-2 INHIBITOR ABT-199 (GDC-0199) IS ACTIVE AND WELL-TOLERATED IN ULTRA HIGH-RISK RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Roberts, A.
    Davids, M.
    Pagel, J.
    Kahl, B.
    Wierda, W.
    Miller, T.
    Gerecitano, J.
    Kipps, T.
    Anderson, M.
    Huang, D.
    Darden, D.
    Gressick, L.
    Nolan, C.
    Yang, J.
    Busman, T.
    Graham, A.
    Cerri, E.
    Enschede, S.
    Humerickhouse, R.
    Seymour, J.
    HAEMATOLOGICA, 2013, 98 : 473 - 473
  • [25] REDUCTION OF TUMOR LYSIS SYNDROME (TLS) RISK IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH ABT-199 (GDC-0199): RESULTS OF MODIFICATIONS TO DOSING SCHEDULE AND TLS PROPHYLAXIS
    Seymour, J.
    Roberts, A.
    Stilgenbauer, S.
    Gressick, L. A.
    Rudersdorf, N. K.
    Busman, T.
    Munasinghe, W.
    Wong, S.
    Desai, M.
    Best, A. E.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    HAEMATOLOGICA, 2014, 99 : 321 - 321
  • [26] A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphosytic leukemia (CLL) harboring 17p deletion
    Wierda, William G.
    Seymour, John Francis
    Roberts, Andrew Warwick
    Puvvada, Soham
    Davids, Matthew Steven
    Wong, Shekman
    Zhu, Ming
    Carrl, Elisa
    Humerickhouse, Rod
    Stilgenbauer, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] ABT-199 (GDC-0199) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA: HIGH RESPONSE RATES AMONG PATIENTS WITH HIGH RISK DISEASE FEATURES INCLUDING UNMUTATED IGHV
    Seymour, J. F.
    Davids, M. S.
    Pagel, J. M.
    Kahl, B. S.
    Wierda, W. G.
    Puvvada, S.
    Gerecitano, J. F.
    Kipps, T. J.
    Anderson, M. A.
    Huang, D. C.
    Rudersdorf, N. K.
    Gressick, L. A.
    Montalvo, N. P.
    Yang, J.
    Zhu, M.
    Dunbar, M.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    Roberts, A. W.
    HAEMATOLOGICA, 2014, 99 : 249 - 249
  • [28] ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY
    Roberts, A. W.
    Ma, S.
    Kipps, T.
    Barrientos, J. C.
    Davids, M. S.
    Anderson, M. A.
    Tam, C.
    Mason-Bright, T.
    Rudersdorf, N. K.
    Yang, J.
    Munasinghe, W.
    Zhu, M.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    Seymour, J. F.
    HAEMATOLOGICA, 2014, 99 : 249 - 249
  • [29] Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Flinn, Ian
    Brunvand, Mark
    Dyer, Martin J. S.
    Hillman, Peter
    Jones, Jeffrey
    Lymp, James
    Elhamy, Mostafa
    Vosganian, Gregory
    Huang, Jane
    Kipps, Thomas J.
    BLOOD, 2014, 124 (21)
  • [30] Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions
    Portell, Craig A.
    Axelrod, Mark
    Brett, L. Kyle
    Gordon, Vicki L.
    Capaldo, Brian
    Xing, Jeffrey C.
    Bekiranov, Stephan
    Williams, Michael E.
    Weber, Michael J.
    BLOOD, 2014, 124 (21)
12345